Zeal Therapeutics

Zeal Therapeutics has developed a proprietary carbohydrate-conjugated drug delivery system ("RENTAC") that leverages endogenous megalin and cubilin receptors in the kidneys to deliver siRNA and small molecules directly into renal cells. The company’s lead program targets progressive kidney disease with preclinical validation ongoing. The team includes leaders in nucleic acid therapeutics and aims for rapid clinical translation due to the validated nature of their approach.

Early results suggest improved targeting efficiency and safety profile compared to non-targeted approaches. The company also plans expansion into broader RNA editing applications and improved small molecule performance.

No clinical trial data or human results have been published as of November 2024.

Pipeline breadth likely limited at this early stage but with intent for broad application.

Key partnerships include academic collaborations with University of Connecticut School of Pharmacy, Harvard Medical School/Beth Israel Deaconess Medical Center/Harvard RNA Medicine Institute.

CEO Iva Toudjarska brings experience from Alnylam; co-founders include Frank Slack (Harvard) and Devparna Bahal.

No evidence found that Zeal Therapeutics has been acquired or merged as of June 2025.